Volume 84, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



With several candidate dengue vaccines under development, this is an important time to help stakeholders (e.g., policy makers, scientists, clinicians, and manufacturers) better understand the potential economic value (cost-effectiveness) of a dengue vaccine, especially while vaccine characteristics and strategies might be readily altered. We developed a decision analytic Markov simulation model to evaluate the potential health and economic value of administering a dengue vaccine to an individual (≤ 1 year of age) in Thailand from the societal perspective. Sensitivity analyses evaluated the effects of ranging various vaccine (e.g., cost, efficacy, side effect), epidemiological (dengue risk), and disease (treatment-seeking behavior) characteristics. A ≥ 50% efficacious vaccine was highly cost-effective [< 1× per capita gross domestic product (GDP) ($4,289)] up to a total vaccination cost of $60 and cost-effective [< 3× per capita GDP ($12,868)] up to a total vaccination cost of $200. When the total vaccine series was $1.50, many scenarios were cost saving.


Article metrics loading...

Loading full text...

Full text loading...



  1. Pediatric Dengue Vaccine Initiative, 2009. Global Burden of Disease. Available at: http://www.pdvi.org/about_dengue/GBD.asp. Accessed December 20, 2010.
  2. Shepard DS, Suaya JA, Halstead SB, Nathan MB, Gubler DJ, Mahoney RT, Wang DN, Meltzer MI, , 2004. Cost-effectiveness of a pediatric dengue vaccine. Vaccine 22: 12751280.[Crossref]
  3. Nagao Y, Koelle K, , 2008. Decreases in dengue transmission may act to increase the incidence of dengue hemorrhagic fever. Proc Natl Acad Sci USA 105: 22382243.[Crossref]
  4. Suaya JA, Shepard DS, Chang MS, Caram M, Hoyer S, Socheat D, Chantha N, Nathan MB, , 2007. Cost-effectiveness of annual targeted larviciding campaigns in Cambodia against the dengue vector Aedes aegypti . Trop Med Int Health 12: 10261036.[Crossref]
  5. Lambrechts L, Scott TW, Gubler DJ, , 2010. Consequences of the expanding global distribution of Aedes albopictus for dengue virus transmission. PLoS Negl Trop Dis 4: e646.[Crossref]
  6. Chikaki E, Ishikawa H, , 2009. A dengue transmission model in Thailand considering sequential infections with all four serotypes. J Infect Dev Ctries 3: 711722.[Crossref]
  7. Fried JR, Gibbons RV, Kalayanarooj S, Thomas SJ, Srikiatkhachorn A, Yoon IK, Jarman RG, Green S, Rothman AL, Cummings DA, , 2010. Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006. PLoS Negl Trop Dis 4: e617.[Crossref]
  8. Halstead SB, Nimmannitya S, Cohen SN, , 1970. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med 42: 311328.
  9. Burke DS, Nisalak A, Johnson DE, Scott RM, , 1988. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 38: 172180.
  10. Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, Salitul V, Phanthumachinda B, Halstead SB, , 1984. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 120: 653669.[Crossref]
  11. Durbin AP, Whitehead SS, , 2010. Dengue vaccine candidates in development. Curr Top Microbiol Immunol 338: 129143.
  12. Webster DP, Farrar J, Rowland-Jones S, , 2009. Progress towards a dengue vaccine. Lancet Infect Dis 9: 678687.[Crossref]
  13. Lang J, , 2009. Recent progress on Sanofi Pasteur's dengue vaccine candidate. J Clin Virol 46 (Suppl 2): S20S24.[Crossref]
  14. Sanofi-Aventis Study of ChimeriVax Dengue Tetravalent Vaccine in Adult Subjects, 2008. Available at: http://clinicaltrials.gov/ct2/show/NCT00730288. NLM Identifier NCT00730288. Accessed August 17, 2010.
  15. Voelker R, , 2010. Race is on for effective dengue vaccine. JAMA 304: 14301431.[Crossref]
  16. Lee BY, Burke DS, , 2010. Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles. Vaccine 28: 28062809.[Crossref]
  17. Baly A, Toledo ME, Boelaert M, Reyes A, Vanlerberghe V, Ceballos E, Carvajal M, Maso R, La Rosa M, Denis O, Van der Stuyft P, , 2007. Cost effectiveness of Aedes aegypti control programmes: participatory versus vertical. Trans R Soc Trop Med Hyg 101: 578586.[Crossref]
  18. McConnell KJ, Gubler DJ, , 2003. Guidelines on the cost-effectiveness of larval control programs to reduce dengue transmission in Puerto Rico. Rev Panam Salud Publica 14: 916.[Crossref]
  19. Kliks SC, Nimmanitya S, Nisalak A, Burke DS, , 1988. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 38: 411419.
  20. World Health Organization, 2008. Global Health Observatory. Available at: http://apps.who.int/ghodata/?vid=720. Accessed October 20, 2010.
  21. Guzman MG, Kouri GP, Bravo J, Soler M, Vazquez S, Morier L, , 1990. Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg 42: 179184.
  22. Bureau of Epidemiology, 2009. Bureau of Epidemiology. Available at: http://epid.moph.go.th/http://epid.moph.go.th. Accessed May 21, 2010.
  23. Vellozzi C, Mitchell T, Miller E, Casey CG, Eidex RB, Hayes EB, , 2006. Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: eleven United States cases, 1996–2004. Am J Trop Med Hyg 75: 333336.
  24. Centers for Disease Control and Prevention, 2004. Yellow Fever Vaccine: What You Need to Know. Atlanta, GA: Centers for Disease Control and Prevention.
  25. Centers for Disease Control and Prevention, 2010. Japanese Encephalitis Vaccine: What You Need to Know. Atlanta, GA: Centers for Disease Control and Prevention, 2.
  26. Anderson KB, Chunsuttiwat S, Nisalak A, Mammen MP, Libraty DH, Rothman AL, Green S, Vaughn DW, Ennis FA, Endy TP, , 2007. Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study. Lancet 369: 14521459.[Crossref]
  27. World Health Organization, 2004. Global Burden of Disease 2004 Update: World Health Organization, 9. Geneva: WHO.
  28. Suaya JA, Shepard DS, Siqueira JB, Martelli CT, Lum LC, Tan LH, Kongsin S, Jiamton S, Garrido F, Montoya R, Armien B, Huy R, Castillo L, Caram M, Sah BK, Sughayyar R, Tyo KR, Halstead SB, , 2009. Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. Am J Trop Med Hyg 80: 846855.
  29. Guzman MG, Kouri G, Morier L, Soler M, Fernandez A, , 1984. A study of fatal hemorrhagic dengue cases in Cuba, 1981. Bull Pan Am Health Organ 18: 213220.
  30. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J, , 2010. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 201: 370377.[Crossref]
  31. Chokephaibulkit K, Sirivichayakul C, Thisyakorn U, Sabchareon A, Pancharoen C, Bouckenooghe A, Gailhardou S, Boaz M, Feroldi E, , 2010. Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial. Pediatr Infect Dis J 29: 11111117.[Crossref]
  32. Torresi J, McCarthy K, Feroldi E, Meric C, , 2010. Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials. Vaccine 28: 79938000.[Crossref]
  33. Nasveld PE, Marjason J, Bennett S, Aaskov J, Elliott S, McCarthy K, Kanesa-Thasan N, Feroldi E, Reid M, , 2010. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: Randomized double-blind phase II evaluation of safety and immunogenicity. Hum Vaccin 6: 906914.[Crossref]
  34. World Health Organization, 2009. Choosing Interventions that are Cost Effective (WHO-CHOICE): Cost-effectiveness thresholds. Available at: http://www.who.int/choice/costs/CER_thresholds/en/index.html. Accessed October 20, 2010.
  35. The World Bank, 2010. Data: GDP per capita (current US$). Available at: http://data.worldbank.org/indicator/NY.GDP.PCAP.CD. Accessed July 10, 2010.
  36. Initiative for Vaccine Research, 2008. WHO Guide for Standardization of Economic Evaluations of Immunization Programmes. Geneva: World Health Organization, Department of Immunization Vaccines and Biologicals.
  37. Gold MR, 1996. Cost-effectiveness in health and medicine. New York: Oxford University Press.
  38. Dollar US, (USD) to Thai Baht (THB) exchange rate history. Available at: http://www.exchangerates.org.uk/USD-THB-exchange-rate-history.html. Accessed October 28, 2010.
  39. Wolfson LJ, Gasse F, Lee-Martin SP, Lydon P, Magan A, Tibouti A, Johns B, Hutubessy R, Salama P, Okwo-Bele JM, , 2008. Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006–2015. Bull World Health Organ 86: 2739.[Crossref]
  40. National Institute of Allergy and Infectious Diseases (NIAID), 2010. Evaluation of the safety and immune response of three admixtures of a tetravalent dengue virus vaccine. Available at: http://ClinicalTrials.gov/show/NCT01072786/NLM/Identifier/NCT01072786. Accessed September 29, 2010.
  41. Lee BY, McGlone SM, , 2010. Pricing of new vaccines. Hum Vaccin 6: 619626.[Crossref]
  42. World Health Organization, 2010. WHO-UNICEF estimates of immunization coverage: the Kingdom of Thailand. Available at: http://apps.who.int/immunization_monitoring/en/globalsummary/timeseries/tswucoveragebycountry.cfm?country=THA. Accessed September 20, 2010.
  43. UNICEF, 2008. Thailand Statistics. Available at: www.unicef.org/infobycountry/Thailand.statistics.html. Accessed October 2, 2010.

Data & Media loading...

  • Received : 02 Nov 2010
  • Accepted : 13 Jan 2011

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error